A high content screening assay to predict human drug-induced liver injury during drug discovery

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 3, 2013, Pages 302-313

  Persson, Mikael ^a   Løye, Anni F ^a   Mow, Tomas ^a   Hornberg, Jorrit J ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Cytotoxicity; Drug induced liver injury; Hepatotoxicity; High content screening; Methods; Mitochondrial toxicity; Predictive toxicology; Risk assessment

Indexed keywords

AMINOSALICYLIC ACID; AMIODARONE; AMISULPRIDE; AMITRIPTYLINE; AMODIAQUINE; BICALUTAMIDE; CAFFEINE; CARBIDOPA; CHLORPROMAZINE; CLOZAPINE; CYCLOSPORIN; DANAZOL; DANTROLENE; DICLOFENAC; DIDANOSINE; DISULFIRAM; EFAVIRENZ; ETOPOSIDE; FELBAMATE; FIALURIDINE; HALOPERIDOL; IMIPRAMINE; INDOMETACIN; ITRACONAZOLE; KETOCONAZOLE; KETOROLAC; PARACETAMOL; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; DRUG INDICATION; FALSE POSITIVE RESULT; HIGH CONTENT SCREENING ASSAY; HUMAN; HUMAN CELL; IC 50; LYSOSOME; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL TOXICITY; PREDICTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; TOXICITY TESTING; VALIDATION STUDY;

AC50; ACTIVITY CONCENTRATION 50%; ALANINE TRANSFERASE; ALT; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZINE; CCCP; CMAX; CYTOTOXICITY; DILI; DIMETHYL SULFOXIDE; DMSO; DRUG-INDUCED LIVER INJURY; FBS; FETAL BOVINE SERUM; HCS; HEPATOTOXICITY; HIGH CONTENT SCREENING; IC50; INHIBITORY CONCENTRATION 50%; LEC; LOWEST EFFICACIOUS CONCENTRATION; MAXIMUM TOTAL CONCENTRATION IN PLASMA; METHODS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL TOXICITY; MMP; PBS; PHOSPHATE BUFFERED SALINE; PREDICTIVE TOXICOLOGY; RISK ASSESSMENT; SD; SEM; STANDARD DEVIATION; STANDARD ERROR OF THE MEAN; THERAPEUTIC INTERVAL; TI;

DRUG DESIGN; DRUG DISCOVERY; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEP G2 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84883187061     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.08.001     Document Type: Article

References (39)

1. Abraham V.C., Towne D.L., Waring J.F., Warrior U., Burns D.J. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. Journal of Biomolecular Screening 2008, 13:527-537.
2. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nature Reviews. Drug Discovery 2011, 10:328-329.
3. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nature Reviews. Drug Discovery 2011, 10:87.
4. Begriche K., Massart J., Robin M.A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. Journal of Hepatology 2011, 54:773-794.
5. Benbow J.W., Aubrecht J., Banker M.J., Nettleton D., Aleo M.D. Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies. Toxicology Letters 2010, 197:175-182.
6. Blas-Garcia A., Apostolova N., Ballesteros D., Monleon D., Morales J.M., Rocha M., et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010, 52:115-125.
7. Boelsterli U.A., Lim P.L. Mitochondrial abnormalities - A link to idiosyncratic drug hepatotoxicity?. Toxicology and Applied Pharmacology 2007, 220:92-107.
8. Chalasani N., Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138:2246-2259.
9. Chan K., Truong D., Shangari N., O'Brien P.J. Drug-induced mitochondrial toxicity. Expert Opinion on Drug Metabolism & Toxicology 2005, 1:655-669.
10. Czaja M.J. Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 2011, 140:1895-1908.
11. Dawson S., Stahl S., Paul N., Barber J., Kenna J.G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metabolism and Disposition 2012, 40:130-138.
12. Dykens J.A., Marroquin L.D., Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Review of Molecular Diagnostics 2007, 7:161-175.
13. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discovery Today 2007, 12:777-785.
14. Fung M., Thornton A., Mybeck K., Wu J.H., Hornbuckle K., Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999. Drug Information Journal 2001, 35:293-317.
15. Greer M.L., Barber J., Eakins J., Kenna J.G. Cell based approaches for evaluation of drug-induced liver injury. Toxicology 2010, 268:125-131.
16. Holt M.P., Ju C. Mechanisms of drug-induced liver injury. The AAPS Journal 2006, 8:E48-E54.
17. Homberg J.C., Stelly N., Andreis I., Abuaf N., Saadoun F., Andre J. A new antimitochondria antibody (anti-M6) in iproniazid-induced hepatitis. Clinical and Experimental Immunology 1982, 47:93-102.
18. Kaplowitz N. Drug-induced liver injury. Clinical Infectious Diseases 2004, 38(Suppl. 2):S44-S48.
19. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nature Reviews. Drug Discovery 2005, 4:489-499.
20. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews. Drug Discovery 2004, 3:711-715.
21. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundamental and Clinical Pharmacology 2008, 22:335-353.
22. Lammert C., Einarsson S., Saha C., Niklasson A., Bjornsson E., Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008, 47:2003-2009.
23. Lee W.M. Drug-induced hepatotoxicity. The New England Journal of Medicine 2003, 349:474-485.
24. Lin Z., Will Y. Evaluation of drugs with specific organ toxicities in organ specific cell lines. Toxicological Sciences 2011, 126:114-127.
25. Muller P.Y., Milton M.N. The determination and interpretation of the therapeutic index in drug development. Nature Reviews. Drug Discovery 2012, 11:751-761.
26. Nadanaciva S., Lu S., Gebhard D.F., Jessen B.A., Pennie W.D., Will Y. A high content screening assay for identifying lysosomotropic compounds. Toxicology In Vitro 2011, 25:715-723.
27. Nakayama S., Atsumi R., Takakusa H., Kobayashi Y., Kurihara A., Nagai Y., et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metabolism and Disposition 2009, 37:1970-1977.
28. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Archives of Toxicology 2006, 80:580-604.
29. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 2000, 32:56-67.
30. Otto M., Hansen S.H., Dalgaard L., Dubois J., Badolo L. Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. Cell Biology and Toxicology 2008, 24:87-99.
31. Pessayre D., Fromenty B., Berson A., Robin M.A., Lettéron P., Moreau R., et al. Central role of mitochondria in drug-induced liver injury. Drug Metabolism Reviews 2012, 44:34-87.
32. Pons C., Dansette P.M., Gregeois J., Homberg J.C., Billett E.E., Mansuy D. Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. Biochemical and Biophysical Research Communications 1996, 218:118-124.
33. Russmann S., Kullak-Ublick G.A., Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Current Medicinal Chemistry 2009, 16:3041-3053.
34. Schneider P., Korolenko T.A., Busch U. A review of drug-induced lysosomal disorders of the liver in man and laboratory animals. Microscopy Research and Technique 1997, 36:253-275.
35. Stepan A.F., Walker D.P., Bauman J., Price D.A., Baillie T.A., Kalgutkar A.S., et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chemical Research in Toxicology 2011, 24:1345-1410.
36. Stevens J.L., Baker T.K. The future of drug safety testing: Expanding the view and narrowing the focus. Drug Discovery Today 2009, 14:162-167.
37. Thompson R.A., Isin E.M., Li Y., Weidolf L., Page K., Wilson I., et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chemical Research in Toxicology 2012, 25:1616-1632.
38. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de G.D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicological Sciences 2008, 105:97-105.
39. Zhang H., Solomon V.R., Hu C., Ulibarri G., Lee H. Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives. Biomedicine and Pharmacotherapy 2008, 62:65-69.